Alumis Inc.

Healthcare · Biotechnology · United States

Last price 6.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 871.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e...